Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this trial will be to investigate the dose-response relationship of 4 doses of CHF 6001 DPI with respect to predose FEV1 after 12 weeks of treatment and to identify the optimal dose of CHF 6001 for further development in the target patient population.
Critère d'inclusion
- Chronic Obstructive Pulmonary Disease (COPD)